Xcelience, a contract development and manufacturing organization (CDMO), has made a structured cash investment in Powdersize, a Pennsylvania-based company specializing in milling, micronization and powder size classification within the pharmaceutical industry. This investment will help grow Powdersize’s business while simultaneously adding a complete set of particle size control solutions to Xcelience’s portfolio of capabilities.

“As we continue to build our suite of services, we are excited to join with Powdersize in an integration that combines their leadership and 23 years of milling and micronizing experience, with our two decades of expertise in drug development,” said Derek Hennecke, president and chief executive officer, Xcelience.  “We believe this integration with Powdersize will allow us to deliver greater speed to clinic through exceptional science and extensive capabilities.”

Many drugs in pharmaceutical development are poorly soluble. Reducing particle size through micronization is considered the leading technology for increasing the bioavailability of oral dosage forms when the API has solubility issues. Current industry trends increasingly demand micronization of APIs with particle sizes of 1-10µm. 

“This collaboration is a natural fit for both sides,” said Wayne Sigler, chief executive officer, Powdersize. “We fully expect both companies to benefit from each other’s strengths and capabilities in drug development and commercial products.” 

Powdersize will continue with expansion plans in a recently added, state-of-the-art facility, to support the additional business expected with the integration and shared development projects.

“By integrating with Powdersize, we will be able to do more in fewer steps,” Mr. Hennecke said. “That means faster time to clinic. It also supports our mission to provide clients with unprecedented levels of innovation and industry-leading expertise to best advance their development and commercial pursuits.”